Literature DB >> 17009837

Pharmacokinetics of telmisartan in healthy Chinese subjects after oral administration of two dosage levels.

Peng Zhang1, Yifan Zhang, Xiaoyan Chen, Rongqin Li, Jian Yin, Dafang Zhong.   

Abstract

To study the pharmacolkinetics of telmisartan in healthy Chinese male subjects after oral administration of two dosage levels, 36 healthy subjects were divided into two groups and given a single oral dose of 40 or 80 mg telmisartan (CAS 144701-48-4, MicardisPlus). A sensitive liquid chromatography-tandem mass spectrometry method (LC-MS-MS) was used for the determination of telmisartan in plasma. Both, a non-compartmental and compartmental method were used for analysis of parameters of kinetics. The main pharmacokinetic parameters of the 40 mg and 80 mg regimen group were as follows: t(max) (1.76 +/- 1.75) h, (1.56 +/- 1.09) h, C(max) (163.2 +/- 128.4) ng/mL, (905.7 +/- 583.4) ng/mL, t1/2 (23.6 +/- 10.8) h, (23.0 +/- 6.4) h, AUC(o-t) (1456 +/- 1072) ng x h/mL, (6759 +/- 3754) ng x h/mL, AUC(o-infinity (1611 +/- 1180) ng x h/mL, (7588 +/- 4661) ng x h/mL, respectively. After dose normalization, there was significant difference for main pharmacokinetic parameters C(max) AUC(o-t) and AUC(o-infinity) between two dosage level groups. The plasma concentration-time profile of telmisartan was characterized by a high degree of inter-individual variability and the disposition of telmisartan in healthy Chinese subjects was dose-dependent. The pharmacokinetic parameters C(max) and AUC(o-inifinity) of the 80 mg regimen group increased to about 5-fold compared to that of the 40 mg regimen group, but there was no significant difference for t(max) and t1/2 between the two dose groups.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17009837     DOI: 10.1055/s-0031-1296753

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  7 in total

1.  Telmisartan Inhibits the NLRP3 Inflammasome by Activating the PI3K Pathway in Neural Stem Cells Injured by Oxygen-Glucose Deprivation.

Authors:  Hyuk Sung Kwon; Jungsoon Ha; Ji Young Kim; Hyun-Hee Park; Eun-Hye Lee; Hojin Choi; Kyu-Yong Lee; Young Joo Lee; Seong-Ho Koh
Journal:  Mol Neurobiol       Date:  2021-01-06       Impact factor: 5.590

2.  Effects of UGT1A1 Polymorphism, Gender and Triglyceride on the Pharmacokinetics of Telmisartan in Chinese Patients with Hypertension: A Population Pharmacokinetic Analysis.

Authors:  Lu Huang; Liu Yang; Jie Huang; Hong-Yi Tan; Shi-Kun Liu; Cheng-Xian Guo; Xiao-Cong Zuo; Guo-Ping Yang; Qi Pei
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-12       Impact factor: 2.441

3.  Synchronous Spectrofluorimetry Coupled with Third-Order Derivative Signal Processing for the Simultaneous Quantitation of Telmisartan and Chlorthalidone Drug Combination in Human Plasma.

Authors:  Ahmed Elsonbaty; Mohamed A Hasan; Maya S Eissa; Wafaa S Hassan; Sara Abdulwahab
Journal:  J Fluoresc       Date:  2020-10-22       Impact factor: 2.217

4.  Polymorphism of ORM1 is associated with the pharmacokinetics of telmisartan.

Authors:  Wang-Qing Chen; Yan Shu; Qing Li; Lin-Yong Xu; Mary W Roederer; Lan Fan; Lan-Xiang Wu; Fa-Zhong He; Jian-Quan Luo; Zhi-Rong Tan; Yi-Jing He; Hong-Hao Zhou; Xiang Chen; Wei Zhang
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

5.  Physiologically-based pharmacokinetic predictions of intestinal BCRP-mediated drug interactions of rosuvastatin in Koreans.

Authors:  Soo Hyeon Bae; Wan-Su Park; Seunghoon Han; Gab-Jin Park; Jongtae Lee; Taegon Hong; Sangil Jeon; Dong-Seok Yim
Journal:  Korean J Physiol Pharmacol       Date:  2018-04-25       Impact factor: 2.016

6.  Telmisartan increases hepatic glucose production via protein kinase C ζ-dependent insulin receptor substrate-1 phosphorylation in HepG2 cells and mouse liver.

Authors:  Kae Won Cho; Du-Hyong Cho
Journal:  Yeungnam Univ J Med       Date:  2018-12-20

7.  Telmisartan Inhibits Nitric Oxide Production and Vessel Relaxation via Protein Phosphatase 2A-mediated Endothelial NO Synthase-Ser1179 Dephosphorylation.

Authors:  Du Hyong Cho
Journal:  J Korean Med Sci       Date:  2019-11-04       Impact factor: 2.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.